IL179240A - Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody - Google Patents

Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody

Info

Publication number
IL179240A
IL179240A IL179240A IL17924006A IL179240A IL 179240 A IL179240 A IL 179240A IL 179240 A IL179240 A IL 179240A IL 17924006 A IL17924006 A IL 17924006A IL 179240 A IL179240 A IL 179240A
Authority
IL
Israel
Prior art keywords
antibody
allograft
medicaments
prolong
survival
Prior art date
Application number
IL179240A
Other languages
English (en)
Hebrew (he)
Other versions
IL179240A0 (en
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL179240(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of IL179240A0 publication Critical patent/IL179240A0/en
Publication of IL179240A publication Critical patent/IL179240A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL179240A 2004-05-14 2006-11-13 Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody IL179240A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57144404P 2004-05-14 2004-05-14
PCT/US2005/017048 WO2005110481A2 (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity

Publications (2)

Publication Number Publication Date
IL179240A0 IL179240A0 (en) 2007-03-08
IL179240A true IL179240A (en) 2014-07-31

Family

ID=35385551

Family Applications (2)

Application Number Title Priority Date Filing Date
IL179240A IL179240A (en) 2004-05-14 2006-11-13 Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody
IL233326A IL233326A0 (en) 2004-05-14 2014-06-23 Extending the survival of donor tissue by inhibiting the activity of complement

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL233326A IL233326A0 (en) 2004-05-14 2014-06-23 Extending the survival of donor tissue by inhibiting the activity of complement

Country Status (14)

Country Link
US (3) US20090028850A1 (https=)
EP (4) EP2338511A3 (https=)
JP (3) JP5161567B2 (https=)
AU (1) AU2005244012C1 (https=)
CA (1) CA2566716C (https=)
DK (1) DK1755674T3 (https=)
ES (1) ES2528362T3 (https=)
HK (2) HK1201758A1 (https=)
IL (2) IL179240A (https=)
NZ (1) NZ551308A (https=)
PL (1) PL1755674T3 (https=)
PT (1) PT1755674E (https=)
SI (1) SI1755674T1 (https=)
WO (1) WO2005110481A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
JP5722524B2 (ja) * 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
WO2011003098A1 (en) * 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
CA2920293A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
US20180311299A1 (en) * 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系
EP4619020A1 (en) * 2022-12-08 2025-09-24 NovMetaPharma Co., Ltd. Composition and method for prolong survival of transplant and recipient

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
AU9149791A (en) * 1990-12-06 1992-07-08 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
AU748443B2 (en) * 1998-02-04 2002-06-06 General Hospital Corporation, The Costimulatory blockade and mixed chimerism in transplantation
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
WO2000027421A2 (en) 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
EP2896631A1 (en) * 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
BR0209319A (pt) * 2001-06-08 2004-07-20 Novartis Ag Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina
ES2283594T5 (es) 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
AU2003209308A1 (en) 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
US7923010B2 (en) * 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
BRPI0511272A (pt) * 2004-05-17 2007-12-04 Combinatorx Inc métodos e reagentes para o tratamento de distúrbios imunoinflamatórios

Also Published As

Publication number Publication date
ES2528362T3 (es) 2015-02-09
WO2005110481A2 (en) 2005-11-24
JP2007537299A (ja) 2007-12-20
NZ551308A (en) 2009-06-26
US20090028850A1 (en) 2009-01-29
CA2566716C (en) 2014-12-23
EP1755674B1 (en) 2014-11-19
WO2005110481A3 (en) 2006-06-22
HK1222342A1 (en) 2017-06-30
US20170267751A1 (en) 2017-09-21
AU2005244012B2 (en) 2011-08-18
JP5161567B2 (ja) 2013-03-13
EP2338511A2 (en) 2011-06-29
HK1201758A1 (en) 2015-09-11
US20190309053A1 (en) 2019-10-10
DK1755674T3 (en) 2015-02-09
IL179240A0 (en) 2007-03-08
JP2013032391A (ja) 2013-02-14
JP2014080438A (ja) 2014-05-08
IL233326A0 (en) 2014-08-31
PL1755674T3 (pl) 2015-05-29
EP2338511A3 (en) 2012-07-25
AU2005244012C1 (en) 2013-05-02
PT1755674E (pt) 2015-02-05
SI1755674T1 (sl) 2015-04-30
HK1101962A1 (en) 2007-11-02
AU2005244012B9 (en) 2011-11-03
EP3056218A1 (en) 2016-08-17
CA2566716A1 (en) 2005-11-24
EP2815767A1 (en) 2014-12-24
AU2005244012A1 (en) 2005-11-24
EP1755674A2 (en) 2007-02-28
JP5590624B2 (ja) 2014-09-17

Similar Documents

Publication Publication Date Title
IL179240A (en) Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody
IL186162A (en) Spray drug containing amikacin and systems and devices for giving
PL2985026T3 (pl) Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje
IL191117A (en) Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
IL186671A (en) Monoclonal antibodies that bind specifically to the amyloid-cell peptide, methods of making them, pharmaceutical preparations that include them and their use in the manufacture of drugs
IL196167A0 (en) Bicyclic compounds and pharmaceutical compositions containing the same
EP1973593A4 (en) DEVICES FOR DISPENSING AND STORING MEDICAMENTS AND SYSTEMS COMPRISING THE SAME
IL189876A0 (en) Pharmaceutical formulations containing anti-cd3 antibody
GB2402063B (en) Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof
IL188151A0 (en) ANTIBODIES THAT BIND TO HUMAN PDGFRd AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL176749A0 (en) ANTIBODIES TO MAdCAM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ZA200809998B (en) Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
IL198578A0 (en) Unit dosage package and methods for administering weight loss medications
IL245365A0 (en) ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses
CL2007003855A1 (es) Composicion que comprende un vehiculo sustrato y un deposito sobre dicho vehiculo sustrato, donde dicho deposito comprende particulas de un compuesto derivado de pregnano; capsula y tableta que la comprenden; y uso en el tratamiento de enfermedades t
IL187224A0 (en) Bicyclic derivatives and pharmaceutical compositions containing the same
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
EP2220081A4 (en) GLUCCOAINEACTIVATORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES
IL190017A0 (en) Bicyclic compounds and pharmaceutical compositions containing the same
IL186854A0 (en) Urea derivatives and pharmaceutical compositions containing the same
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
ZA200701443B (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
ZA200901212B (en) Improvements of the biovailability of active substances having an amidine function in medicaments
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees